Objective: We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson’s disease (PD) with large population.

Background: EDS and depression is common in PD. Ropinirole was suggested to be associated with EDS, and it was reported to improve depression, but the results have been conflicting.

Methods: We conducted cross-sectional observational study at nine hospitals in Korea between April 24, 2013 and April 22, 2015. We analyzed demographic and clinical features, other medical history, the history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), the Unified Parkinson’s Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).

Results: 413 patients with PD (mean age: 65.19 ± 8.98 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, motor fluctuation, total LEDD, and levodopa dose were independent risk factors for EDS, and that sex, UPDRS II, and EDS were independent risk factors for depression.

Conclusions: Our large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients. Younger age, lower level of routine daily activities, motor symptoms fluctuation, lower total levodopa equivalent daily doses, and higher levodopa dose were independent risk factors for EDS. Women, lower level of daily activities, and EDS were independent risk factors for depression.

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/sleepiness-and-depression-in-korean-patients-with-parkinsons-disease-treated-with-ropinirole-and-levodopa/